Gout Therapeutics Market to be Worth $4.13 Billion by 2030: Grand View Research, Inc.

Read full market research report with ToC, "Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease Condition (Acute, Chronic), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read full market research report with ToC, " Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease Condition (Acute,...

Read full market research report with ToC, "Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease Condition (Acute, Chronic), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research.

Gout Therapeutics Market Growth & Trends

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Scope

 

Gout Therapeutics Market Segmentation

Grand View Research has segmented the global gout therapeutics market based on drug class, disease condition, distribution channel, and region:

Gout Therapeutics Market - Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

Gout Therapeutics Market - Disease Condition Outlook (Revenue, USD Million, 2018 - 2030)

Gout Therapeutics Market - Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Gout Therapeutics Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)

List of Key Players in the Gout Therapeutics Market

Check out more related studies published by Grand View Research:

Browse through Grand View Research's  Pharmaceuticals Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Grand View Compass | Pipeline Consulting
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/gout-therapeutics-market-to-be-worth-4-13-billion-by-2030-grand-view-research-inc-301880918.html